Honored by the 7th JLDHTP as Scientific and Technical Leading Talent, Yang Dajun pursued his doctor's degree in cancer genetics at Michigan State University, and has got 20-plus years’ experience in cancer research and drug development. His projects won the support of Ministry of Science and Technology's International S&T Cooperation Program of China, Major New Drug Creation Program, 863 Program, etc.

"Ascentage Pharma is dedicated to the design, R&D, transformation and industrialization research of international original drugs," said Yang. The company has up to now finished the reserve of eight international original new drugs, with its products ranging from anti-cancer, hepatitis B, age-related macular degeneration drugs to the drugs that treat aging related diseases.

Biomedicine is a long period and high risk industry to Yang, while SIP's industry development policies are highly sustainable. "The aggregation effect of the biomedicine industry has taken shape in SIP; SIP also boasts a self-contained supporting investment and financing environment, and half of our last year's financing comes from SIP."

"In the future, SIP will probably become China's Silicon Valley in biomedicine," said Yang. Attracted by SIP's sound entrepreneurship environment, large numbers of biomedical talents and teams have settled down here.

"The talent aggregation effect has driven the development of SIP's biomedicine industry. In the coming three to five years, SIP will have a batch of new drugs hit the market, which is also the only criterion for measuring the development of biomedicine industry in a district."